Paul Jeng
Stock Analyst at Guggenheim
(3.04)
# 1,223
Out of 5,170 analysts
7
Total ratings
83.33%
Success rate
73.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterates: Buy | $50 | $32.60 | +53.37% | 2 | Feb 18, 2026 | |
| ADAG Adagene | Initiates: Buy | $9 | $3.69 | +143.90% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $9.69 | +96.08% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $30.04 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $2.99 | +67.22% | 1 | Sep 18, 2025 |
IDEAYA Biosciences
Feb 18, 2026
Reiterates: Buy
Price Target: $50
Current: $32.60
Upside: +53.37%
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $3.69
Upside: +143.90%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $9.69
Upside: +96.08%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $30.04
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $2.99
Upside: +67.22%